Compare
Theriva Biologics, Inc. vs China SXT Pharmaceuticals, Inc. vs BioXcel Therapeutics, Inc. vs Verrica Pharmaceuticals Inc.
| Latest fiscal year | Theriva Biologics, Inc. TOVX | China SXT Pharmaceuticals, Inc. SXTC | BioXcel Therapeutics, Inc. BTAIQ | Verrica Pharmaceuticals Inc. VRCA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.14M | $642.0K | $35.58M |
| Revenue growth (YoY) | n/a | -34.6% | -71.7% | +370.2% |
| Gross margin | n/a | 21.9% | 74.5% (computed) | n/a |
| Operating margin | n/a | -625.9% | n/m | -34.2% |
| Net margin | n/a | -545.2% | n/m | -50.3% |
| Net income | -$23.74M | -$6.21M | -$69.90M | -$17.89M |
| EPS (Diluted) | -$2.08 | -$9.13 | -$5.73 | -$1.68 |
| Operating cash flow | -$16.67M | -$4.02M | -$57.62M | -$17.63M |
| Free cash flow | -$16.70M | n/a | -$57.62M | -$17.63M |
| Cash & equivalents | $13.06M | $28.18M | $28.41M | $30.15M |
| Total assets | $38.24M | $34.75M | $44.92M | $47.13M |
| Total liabilities | $22.86M | $5.05M | $140.38M | $22.39M |
| Shareholders' equity | $15.38M | $29.71M | -$95.46M | $24.74M |
| Return on year-end equity | -154.3% | -20.9% | n/a | -72.3% |
| Shares outstanding | 35.69M | n/a | 22.33M | 17.18M |
Revenue, most recent five fiscal years
| Fiscal year | Theriva Biologics, Inc. | China SXT Pharmaceuticals, Inc. | BioXcel Therapeutics, Inc. | Verrica Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2011-12-31 | $1.14M Ended 2026-03-31 | $642.0K Ended 2025-12-31 | $35.58M Ended 2025-12-31 |
| 1 year earlier | $2.61M Ended 2010-12-31 | $1.74M Ended 2025-03-31 | $2.27M Ended 2024-12-31 | $7.57M Ended 2024-12-31 |
| 2 years earlier | n/a | $1.93M Ended 2024-03-31 | $1.38M Ended 2023-12-31 | $5.12M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.97M Ended 2023-03-31 | $375.0K Ended 2022-12-31 | $9.03M Ended 2022-12-31 |
| 4 years earlier | n/a | $2.60M Ended 2022-03-31 | n/a | $12.00M Ended 2021-12-31 |